[Invasive treatment of chronic coronary syndrome].

Abstract

The 2024 guidelines of the European Society of Cardiology for the treatment of chronic coronary syndrome provide a comprehensive overview covering prevention, diagnostics, as well as pharmacological and invasive therapies. Based on the latest scientific evidence, the guidelines for myocardial revascularization, valid since 2018, have been updated, and treatment recommendations have been adjusted accordingly. Myocardial revascularization, as an adjunct to optimal pharmacological therapy, remains a key treatment strategy for symptom relief, as well as for improving quality of life and long-term clinical outcomes in patients with chronic coronary syndrome. The decision between percutaneous coronary intervention and coronary artery bypass surgery depends on the anatomical complexity and functional severity of coronary artery disease, as well as comorbidities, patient preferences, and expectations. A careful risk-benefit assessment and an individualized treatment approach are essential to ensure optimal care for each patient. The current guidelines provide an evidence-based framework for this complex decision-making process.